AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double‐blind, efficacy, and safety study

• Autores principales: Jacob M. vanLaar (Autor), Alejhandra Lei (Autor), Mary Safy‐Khan (Autor), Joachim Almquist (Autor), Graham Belfield (Autor), Karl Edman (Autor), Lisa Öberg (Autor), Bastian R. Angermann (Autor), Inken Dillmann (Autor), Pia Berntsson (Autor), Damla Etal (Autor), Ian Dainty (Autor), Carol Astbury (Autor), Maria G. Belvisi (Autor), Szilárd Nemes (Autor), Adam Platt (Autor), Susanne Prothon (Autor), Sara Samuelsson (Autor), Petter Svanberg (Autor), Christina Keen (Autor), the SEMRA study group (Autor)
• Formato: Libro
• Publicado: Wiley, 2023-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Oral corticosteroid use is limited by side effects, some caused by off‐target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 is a selective, nonsteroidal glucocorticoid receptor modulator. The efficacy, safety, and tolerability of AZD9567 and prednisolon...